Evidence-based GLP-1 care.
Individualized to the patient.

GLP-1 receptor agonists mimic signaling from the naturally occurring glucagon-like peptide-1 hormone. Depending on the medication, they can reduce appetite and energy intake, slow gastric emptying, and affect glucose-dependent insulin and glucagon signaling. Tirzepatide also activates the GIP receptor. These medications are used alongside nutrition and physical activity rather than as stand-alone replacements for them.

Wegovy contains semaglutide and acts at the GLP-1 receptor. Current FDA labeling includes both subcutaneous injection and oral tablet formulations for appropriate adult indications. Zepbound contains tirzepatide, activates both GIP and GLP-1 receptors, and is administered by subcutaneous injection. They have different indications, dosing instructions, precautions, and clinical-trial data, so medication selection should be individualized.

FDA has determined that the national shortages of semaglutide injection and tirzepatide injection are resolved. The shortage-based enforcement-discretion periods that allowed broader routine copying ended in 2025. Compounding may still be permissible in limited patient-specific circumstances when federal and state requirements are met, but compounded drugs are not FDA-approved. Mindfuse Health does not routinely use compounded semaglutide or tirzepatide as substitutes for commercially available FDA-approved products.

Not every patient needs the same laboratory testing. Your clinician may use recent results or order testing when clinically indicated based on your history, medications, metabolic risk, and the medication being considered. Testing is individualized rather than ordered as a fixed panel for everyone.

Mindfuse Health is a direct-pay practice and does not bill insurance for clinical consultation or membership fees. Prescription medication is a separate pharmacy expense. Depending on the product and your health plan, you may use insurance coverage, an eligible manufacturer program, or self-pay. Coverage, prior authorization, eligibility, and pharmacy pricing are determined outside the Mindfuse clinical fee.

For several FDA-approved chronic weight-management medications, adult eligibility includes obesity with a BMI of 30 kg/m² or greater, or overweight with a BMI of 27 kg/m² or greater plus at least one weight-related condition, subject to the specific product label. BMI alone does not determine whether a medication is appropriate. Medical history, contraindications, pregnancy plans, medications, prior treatment, and follow-up needs also matter.

Yes. Contraindications and precautions vary by product. For example, current Wegovy and Zepbound labeling includes contraindications for a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, as well as serious hypersensitivity to the relevant drug or ingredients. Weight-loss treatment with these medications is not used during pregnancy. Other medical issues may also affect medication choice or monitoring.

Appetite and weight can increase again after treatment is stopped, and withdrawal studies of semaglutide and tirzepatide have shown substantial weight regain in many participants. The amount varies between individuals. If treatment needs to stop because of side effects, pregnancy plans, cost, availability, or another reason, your clinician can discuss an appropriate long-term strategy.